Overview
| 别名 | Lactoylglutathione lyase; Aldoketomutase; Glyoxalase I; Glx I; Ketone-aldehyde mutase; Methylglyoxalase; S-D-lactoylglutathione methylglyoxal lyase |
| 基因名 | GLO1 |
| UniProt ID | Q04760 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 1L6-W3-S2 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 20 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:100-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Glyoxalase I (GLO1) is a ubiquitous dimeric zinc metalloenzyme that plays a critical role in the detoxification of cytotoxic alpha-oxoaldehydes, particularly methylglyoxal, a byproduct of glycolysis. It catalyzes the isomerization of hemithioacetals, formed from methylglyoxal and glutathione, into S-D-lactoylglutathione, which is subsequently hydrolyzed by GLO2. This pathway is essential for preventing the accumulation of advanced glycation end-products (AGEs), reducing oxidative stress, and inhibiting apoptosis. Structurally, GLO1 utilizes a zinc-coordinated active site to process enantiomers via ene-diol intermediates. Clinical relevance is firmly established in diabetes, where hyperglycemia-induced methylglyoxal elevation leads to endothelial dysfunction, neuropathy, and nephropathy. Additionally, GLO1 inhibition is explored for its cytotoxic effects in antitumor and antimalarial therapies, while its overexpression is associated with the mitigation of glycation damage in high-glucose environments. |
检测原理